-
Sea of colour as Malaysia's Hindus mark Thaipusam with piercings and prayer
-
Exiled Tibetans choose leaders for lost homeland
-
Afghan returnees in Bamiyan struggle despite new homes
-
Mired in economic trouble, Bangladesh pins hopes on election boost
-
Chinese cash in jewellery at automated gold recyclers as prices soar
-
Israel to partially reopen Gaza's Rafah crossing
-
'Quiet assassin' Rybakina targets world number one after Melbourne win
-
Deportation raids drive Minneapolis immigrant family into hiding
-
Nvidia boss insists 'huge' investment in OpenAI on track
-
'Immortal' Indian comics keep up with changing times
-
With Trump mum, last US-Russia nuclear pact set to end
-
In Sudan's old port of Suakin, dreams of a tourism revival
-
Narco violence dominates as Costa Rica votes for president
-
Snowstorm barrels into southern US as blast of icy weather widens
-
LA Olympic chief 'deeply regrets' flirty Maxwell emails in Epstein files
-
Rose powers to commanding six-shot lead at Torrey Pines
-
Barca wasteful but beat Elche to extend Liga lead
-
Konate cut short compassionate leave to ease Liverpool injury crisis
-
Separatist attacks in Pakistan kill 33, dozens of militants dead
-
Dodgers manager Roberts says Ohtani won't pitch in Classic
-
Arsenal stretch Premier League lead as Chelsea, Liverpool stage comebacks
-
Korda defies cold and wind to lead LPGA opener
-
New head of US mission in Venezuela arrives as ties warm
-
Barca triumph at Elche to extend Liga lead
-
Ekitike, Wirtz give Liverpool sight of bright future in Newcastle win
-
West Indies 'tick boxes' in shortened T20 against South Africa
-
Chelsea have something 'special' says Rosenior
-
De Zerbi 'ready to go to war' to solve Marseille troubles
-
Hornets hold off Wemby's Spurs for sixth NBA win in a row
-
Moyes blasts killjoy booking after Everton's late leveller
-
Ex-prince Andrew again caught up in Epstein scandal
-
Bayern held at Hamburg to open door for Dortmund
-
Atletico stumble to draw at Levante, Villarreal held
-
Chelsea stage impressive fightback to beat West Ham
-
Arsenal stretch Premier League lead, Chelsea fightback breaks Hammers' hearts
-
Napoli edge Fiorentina as injury crisis deepens
-
How Lego got swept up in US-Mexico trade frictions
-
UK rights campaigner Tatchell arrested at pro-Palestinian protest
-
Iran says progress made towards US talks despite attack jitters
-
'Empowering': Ireland's first female sumo wrestler blazes a trail
-
US judge denies Minnesota bid to suspend immigration sweeps
-
Ukraine hit by mass power outages after 'technical malfunction'
-
AC Milan prolong France 'keeper Maignan deal by five years
-
Arteta hails Arsenal's statement rout of Leeds
-
Marseille buckle as Paris FC battle back for draw
-
Protesters demand 'justice' one month after Swiss bar fire
-
Philadelphia's Paul George gets 25-game NBA drugs ban
-
La Rochelle suffer defeat after shock Atonio retirement
-
'It wasn't working': Canada province ends drug decriminalization
-
Kishan, Arshdeep star as India down New Zealand in T20 finale
Ketamine pill treats depression without psychedelic effects: study
A new pill that slowly releases ketamine could treat people with severe depression without giving them the psychedelic side effects of the often-misused drug, early trial results suggested on Monday.
First developed in the 1960s as an anaesthetic, ketamine's hallucinogenic and dissociative effects led to it becoming a party drug dubbed "Special K".
However, mounting research has demonstrated that ketamine is effective for the roughly quarter of people suffering from depression who see little benefit from common anti-depressant drugs.
In many countries, ketamine has been prescribed for depression for years.
US billionaire Elon Musk told CNN in March that he regularly uses a small amount of prescribed ketamine because it is "helpful for getting one out of the negative frame of mind".
The drug has long been administered intravenously in clinics, but more recently a nasal spray using a derivative called esketamine has increased in popularity.
Both can cause patients to have side effects such as dissociation, high blood pressure and an elevated heart rate.
There are also fears that medical use of the drug could slide into abuse.
The pill described in the journal Nature Medicine on Monday takes more than 10 hours to break down in the liver, lead study author Paul Glue told AFP.
"The really interesting feedback from patients is the lack of side effects -- no euphoria, no dissociation," said the researcher at New Zealand's University of Otago.
"I don't think these tablets would appeal to people who are abusing ketamine."
- Electro-shock alternative -
The phase 2 trial involved more than 270 people with depression who had previously tried an average of four different anti-depressant drugs.
More than half taking the ketamine pill went into remission for their depression, while 70 percent of the placebo group relapsed after 13 weeks, the study said.
Julaine Allan, an expert on mental health and addiction at Australia's Charles Sturt University who was not involved in the study, praised the trial while emphasising that more research is needed.
Ketamine does not work for everyone, and the "positive effects may wear off over time," she told AFP.
Michel Hoffmann, a psychiatrist at Geneva University Hospitals, said there is "real enthusiasm" in the medical community for ketamine's potential for treating depression.
"For patients who don't respond to conventional drugs, ketamine offers a way to avoid electro-shock therapy," he told AFP.
This last-resort treatment, which involves sending electric currents through the brain, has been proven to be effective.
But it can cause memory loss -- and some patients fear the procedure after seeing depictions of it in films such as "One Flew Over the Cuckoo's Nest".
- Fears of 'opioid style crisis' -
Some psychiatrists remain hesitant to prescribe ketamine for depression, fearing their patients could end up misusing the drug.
Last year, "Friends" actor Matthew Perry became the latest high-profile death from a ketamine overdose.
US police are investigating how Perry obtained the doses that caused his death -- he had reportedly not had a supervised infusion session for several days.
One potential benefit of quick-acting ketamine seen in previous research is that it could help patients considering suicide.
But there is "the plausible concern that the widespread use of ketamine might trigger a new opioid style crisis," Oxford researcher Riccardo De Giorgi said in a 2022 BMJ editorial.
By ridding ketamine of the side effects sought by some partygoers, the slow-release pill could alleviate some of these concerns.
There were still some side effects from the pill, the most common being headaches, dizziness and anxiety.
More research including phase 3 trials is needed before the drug can be reviewed by national medicine agencies, meaning it will be at least two or three years before patients could potentially access the pills, Glue said.
H.Thompson--AT